Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 1/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 5/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31673022 | 0.86 | KDM4E (0.50) | CDK9DYRK1AKDM4EALDH1A1HPGD | |
| SCHEMBL7356720 | 0.86 | KDM4E (0.59) | CDK9DYRK1AKDM4EALDH1A1HPGD | |
| SCHEMBL7224237 | 0.84 | KDM4E (0.48) | CDK9DYRK1AKDM4EALDH1A1HPGD | |
| SCHEMBL7373630 | 0.82 | KDM4E (0.53) | KDM4EALDH1A1HPGDL3MBTL1POLB | |
| SCHEMBL2857475 | 0.81 | TRPA1 (0.49) | CDK9DYRK1AKDM4EALDH1A1HPGD | |
| SCHEMBL16235687 | 0.80 | MCL1 (0.46) | KDM4EGAAMEN1KMT2AMAPT | |
| SCHEMBL7374645 | 0.80 | PRKAG1 (0.46) | CDK9DYRK1AKDM4EALDH1A1HPGD | |
| SCHEMBL1176205 | 0.79 | PRKAG1 (0.43) | CDK9DYRK1AKDM4EHPGDL3MBTL1 | |
| SCHEMBL1966278 | 0.79 | PRKAG1 (0.43) | CDK9DYRK1AKDM4EALDH1A1HPGD | |
| SCHEMBL8715749 | 0.79 | SRD5A2 (0.49) | L3MBTL1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828179-B1 | NICOTINIC ALPHA-7 RECEPTOR LIGANDS AGAINST CNS-RELATED DISEASES | MEMORY PHARM CORP (US) | 2010-01-20 | — | — | EP | claimed |
| US-20250257051-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AS TYK2 INHIBITORS | 1910 GENETICS INC (US) | 2025-08-14 | — | — | US | disclosed |
| WO-2024026430-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AS TYK2 INHIBITORS | 1910 GENETICS INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-2742040-B1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2016-04-06 | — | — | EP | disclosed |
| US-20140309210-A1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| EP-2742040-A1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| WO-2013024011-A1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-21 | — | — | WO | disclosed |
| US-20100016351-A1 | NICOTINIC ALPHA-7 RECEPTOR LIGANDS AND PREPARATION AND USES THEREOF | NGUYEN TRUC MINH | 2010-01-21 | — | — | US | disclosed |
| EP-1828179-B1 | NICOTINIC ALPHA-7 RECEPTOR LIGANDS AGAINST CNS-RELATED DISEASES | MEMORY PHARM CORP (US) | 2010-01-20 | — | — | EP | disclosed |
| US-7625924-B2 | Nicotinic alpha-7 receptor ligands and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-12-01 | — | — | US | disclosed |
| US-20060167039-A1 | Nicotinic alpha-7 receptor ligands and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-27 | — | — | US | disclosed |
| WO-1991001316-A1 | NEW 9-AZABICYCLO[3.3.1]NONANE-DERIVATE | BEECHAM GROUP PLC (GB) | 1991-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309210-A1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CYP3A43, INSR, CYP2C19 | CDK9 1296/4885DYRK1A 1068/4885KDM4E 3432/4885 |
| US-20060167039-A1 | Nicotinic alpha-7 receptor ligands and preparation and uses thereof | CHRNA7, CHRNA5, CHRNA6 | CDK9 2287/4885DYRK1A 2366/4885KDM4E 3928/4885 |
| US-20100016351-A1 | NICOTINIC ALPHA-7 RECEPTOR LIGANDS AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA6 | CDK9 2287/4885DYRK1A 2366/4885KDM4E 3928/4885 |
| US-20250257051-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AS TYK2 INHIBITORS | TYK2, PDXK, JAK1 | CDK9 20/4885DYRK1A 151/4885KDM4E 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.